STAT November 13, 2024
Elaine Chen

Good morning, lots of news this morning that we’ll get straight into.

Califf: ‘We’ll see what happens’ under Trump

At a cancer research conference yesterday, FDA Commissioner Robert Califf said he’s “disappointed” about the election’s outcome and suggested he’s unsure about the future of the agency under the incoming Trump administration.

The agency’s ability to hire and retain skilled employees may be in jeopardy given Trump ally Robert F. Kennedy Jr.’s hostility to civil servants. Trump has said he plans to give Kennedy, leader of the “Make America Healthy Again” movement, power over health care policy in his administration.

“I’m biased, but I feel like the FDA is at peak performance right now and we’ll just see what happens as...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
Christophe Weber, veteran Takeda CEO, to retire next year
FDA warns GLP-1 compounder over safety rules
Metsera, Maze secure combined $415 million in IPOs
Ozempic-Like Drugs May Hold Risks For Surgical Patients, Officials Say
From discovery to delivery: Finding an investment edge in biopharma services

Share This Article